How long does it take for Obinutuzumab to be effective for membranous nephropathy?

Obinutuzumab is a humanized and glycoengineered type II anti-CD20 monoclonal antibody that has better in vitro B cell cytotoxicity than rituximab. Membranous nephropathy (MN) is the leading cause of nephrotic syndrome in non-diabetic adults. Without treatment, MN patients may develop non-progressive chronic kidney disease or develop end-stage renal disease within 10 years. Otuzumabtargets an epitope on CD20 that is different from the epitope recognized by rituximab, which can cause a stronger B cell apoptotic response.

Otuzumab was well tolerated, including in one patient who had previously experienced an infusion-related anaphylaxis with rituximab. Responses to otuzumab were rapid in studies, with 60% of patients achieving complete or partial remission at 6 months, compared with the 6-month response rate of 35% reported in the membranous nephropathy trial studying rituximab. Furthermore, otuzumab appeared to induce durable responses. All patients who achieved response at 12 months with available follow-up data maintained response and did not require additional doses of otuzumab.

The original drug of Otuzumab has been launched in China and has entered the scope of medical insurance, but it is only reimbursed for patients who meet the indications. Specifications The price of 1000mg (40ml)*1 bottle may be around 9,000 yuan, which is a strictly controlled drug. The price of the Turkish version of Otuzumab Specifications1000mg/40ml per box listed overseas may be around RMB 10,000 (the price may fluctuate due to the exchange rate). The ingredients of the original drugs sold domestically and abroad are basically the same. There is currently no generic version of Otuzumab produced and launched. For more drug information and specific prices, please consult the medical consultant of Yaode.